• Profile
Close

International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma

British Journal of Ophthalmology Jun 13, 2019

Hindsø TG, et al. - Researchers conducted this largest cohort study to characterise the clinical features of ocular adnexa (OA)-extranodal marginal zone B-cell lymphoma (EMZL). Participants in the study were 689 patients (median age was 62 years) with OA-EMZL. From January 1, 1980, through December 31, 2017, data were gathered. Data reported that the median follow-up time was 42 months. At the time of diagnosis, the majority of patients were diagnosed with primary OA-EMZL with Ann Arbor stage IE and American Joint Committee on Cancer stage T2. The most frequently involved anatomical structures were the orbit and the conjunctiva. Data reported that the 5-year, 10-year and 20-year disease-specific survival were 96%, 91% and 90%, respectively. According to findings, EMZL is a tumor that grows slowly and has great long-term survival. In localised OA-EMZL, low-dose EBRT as monotherapy should be considered. In those patients with disseminated disease, rituximab-based chemotherapy should be chosen.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay